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and society because the causes, patient proﬁle, and even symptom
patterns remain diﬃcult to characterise [5]. These substantial challenges in describing long COVID have led patients to self-organise
and perform research to try to expedite the characterization of this
disease and therefore how to best ameliorate the substantial impact that long COVID has had on their lives [6].
Long COVID, a multisystem disease, can occur following either severe, mild, or even asymptomatic SARS-CoV-2 infection [7].
There is currently no accepted deﬁnition of long COVID; however,
it can be broadly deﬁned as delayed recovery from infection with
SARS-CoV-2. Long COVID can occur following cases of COVID-19
that were managed in either inpatient or outpatient settings. It is
characterised by lasting effects of the infection, unexplained persistence of symptoms, or onset of new chronic diseases, for far longer
than would be expected based on typical rates of viral clearance
[8].
Given long COVID’s recent emergence, no standard framework
has yet been established for identifying and assessing associated
symptoms or other clinical features. Furthermore, symptoms frequently reported by long COVID patients are not assessed consistently across studies. A systematic review available as a preprint
evaluated all research on long COVID released prior to January 1,
2021 that included at least 100 patients. Based on the 15 studies
that met the inclusion criteria, the authors identiﬁed 55 symptoms
of long COVID [5](preprint). None of the most common symptoms
were assessed by all 15 studies. The authors concluded that the
symptoms of long COVID are extremely heterogeneous and that
the assessment of these symptoms varies widely among studies.
Another recent systematic review concluded that 73% of individuals who had acute COVID-19 experienced at least one persistent
symptom [9]. However, the authors of the review concluded that
the wide variation in design and quality of the studies limited the
direct comparability and combinability of the data [9]. The wide
range of symptoms attributed to long COVID are highlighted by
an extensive patient-led survey (Patient-Led Research Collaborative). This study conducted deep longitudinal characterization of
the long COVID symptoms and trajectories in suspected and conﬁrmed COVID-19 patients who reported illness lasting more than
28 days [6]. Evaluating data from 3,762 respondents to 257 survey questions, this analysis documented 205 phenotypic features
associated with long COVID. The fact that this patient-led study
characterised 205 phenotypic features, while the studies cited in
the aforementioned systematic review reported only 84 signs or
symptoms and 19 laboratory or imaging measurements [9], suggests that the research community has not yet characterised the
full spectrum of clinical manifestations of long COVID. This signiﬁcant disparity in patient versus clinical characterization motivates the proposed ontological approach to specifying manifestations, which will improve capture and integration of future long
COVID studies.
Deep phenotyping is the precise and comprehensive analysis
of individual phenotypic abnormalities, with a focus on computational accessibility. In the ﬁeld of rare disease, the Human Phenotype Ontology (HPO) has become an international standard for
deep phenotyping that enables integrated computational analysis
of genotype and phenotype for diagnostics, novel disease gene discovery, and translational research [10,11]. The HPO includes a standardised vocabulary of over 16,0 0 0 terms with 37,072 synonyms
that deﬁne phenotypic abnormalities associated with over 7,0 0 0
diseases. This tool enables non-exact matching of sets of phenotypic features (phenotype proﬁle) against known diseases, other
patients, and model organisms. The algorithms have been implemented for computational comparison of abnormalities and for
use in genetic disease diagnostics, and they are the de facto standard for deep phenotyping in the ﬁeld of rare disease. The HPO is
used in a range of projects including the UK’s National Institute

Research in context

Evidence before this study
A majority of survivors of COVID-19 report manifestations
that persist beyond the acute illness, so-called Post-Acute Sequelae of SARS-CoV-2 (PASC, or “long COVID”). Long COVID
can affect even those who were initially mildly symptomatic
or asymptomatic, may include a constellation of neurological, respiratory, cardiovascular, and gastrointestinal symptoms, and is debilitating in some affected individuals. Research on long COVID has been complicated due to heterogeneous study methods and lack of a standard for denoting the
many phenotypic manifestations (different terms to describe
the same symptom or condition).
Added value of this study
We reviewed 303 manuscripts ﬂagged as relevant to
long COVID by CoronaCentral. From these, we identiﬁed 59
manuscripts with 81 cohorts that described 287 clinical manifestations of long COVID. Descriptions (symptoms, laboratory
ﬁndings, imaging results) were mapped to Human Phenotype
Ontology (HPO) terms. We have developed layperson synonyms and deﬁnitions for each of the 287 HPO terms, which
signiﬁcantly improves patient and clinician accessibility.
Implications of all the available evidence
One of the challenges in characterizing long COVID is the
fact that patient-reported symptoms are often not captured
by clinical evaluation or in surveys. To truly characterise long
COVID and therefore stratify patients into subtypes for care
decisions, it is necessary to use shared terminology. This
common set of HPO deﬁnitions will promote integration of
research by translating between patient and clinician descriptions of symptoms. We anticipate that this will be a critical
resource for use in survey instruments and patient apps for
standardizing patient-reporting in the future study of long
COVID.

1. Introduction
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
emerged in late 2019 as the third human coronavirus identiﬁed in
the 21st century. Coronavirus disease 2019 (COVID-19) affects diverse organ systems, including the lungs, digestive tract, kidneys,
heart, and brain [1,2]. As of mid-2021, the full spectrum of the
clinical consequences of COVID-19 is not completely understood.
Individual symptoms and disease severity vary widely among patients during the acute infection, with some patients developing
only mild symptoms or even remaining asymptomatic. In contrast,
others experience acute respiratory distress syndrome (ARDS), sepsis, and other life-threatening conditions [3,4]. As more information about patient recovery has been collected, it has become clear
that a wide range of outcomes can also emerge following the
acute phase of the illness, with some patients experiencing residual symptoms or developing new symptoms long after the initial
infection. This post-acute infection, referred to as long COVID, postacute sequelae of COVID (PASC), or post-acute COVID-19 syndrome
(PACS), represents a signiﬁcant challenge for patients, physicians,
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for Health Research (NIHR) Rare Disease initiatives, the 10 0,0 0 0
Genomes project, the NIH Kidney Precision Medicine Project, and
the NIH Undiagnosed Diseases Project and Network, RD-CONNECT,
SOLVE-RD, and many others [10,12]. Existing publications on the
clinical aspects of long COVID have not used a standard vocabulary
to report phenotypic abnormalities, impeding the search, analysis,
and integration of information relevant to long COVID in databases
such as Medline. Ontologies such as HPO are systematic representations of knowledge that deﬁne terminology in a human-readable
format and deﬁne relationships between concepts in a way that allows computational logical reasoning that supports the integration
and analysis of large amounts of data [13]. The signiﬁcant disparity
in patient versus clinical characterization motivated the proposed
ontological approach to specifying manifestations, which will improve capture and integration of future long COVID studies.

questionnaire. For 51 cohorts, information was collected by clinical
examination, and for 5 cohorts, information was collected by questionnaire and clinical examination (Supplemental Table S1). The
time frame for data collection and follow-up also differed across
studies. Some used a relatively precise window for patient assessment (e.g., 21 days after symptom onset), while others included
participants at various distances from acute SARS-COV-2 infection.
Some studies aimed to collect information only on patients suffering from long COVID, while others collected follow-up information on all patients that had previously had COVID-19 regardless
of whether they currently or ever experienced long COVID. Studies
differed in how they referred to the phenomenon studied. Some
referred to it as long COVID or using a similar term such as postacute COVID-19 syndrome, whereas others discussed the clinical
course or patient recovery without mentioning long COVID specifically. Finally, studies varied widely in the terminology used to describe patient-reported symptoms.
In the 59 publications and 81 cohorts curated for this study
(Supplemental Figure S1), a total of 287 phenotypic abnormalities
were identiﬁed and represented as HPO terms. Of these, 132 terms
were used in only one cohort (24.2%), 51 in two cohorts (9.4%),
and 62 terms in at least 5 cohorts (21.6%). In most cases, multiple synonyms were mapped to the same HPO term; for instance,
Hepatic steatosis (HP:0 0 01397) corresponded to four descriptions
used in the literature (Steatosis, Liver steatosis, Fatty inﬁltration
of liver, Fatty liver). Among terms reported in at least 10 cohorts
(n=31 terms), the most commonly reported feature was Fatigue
(median 45.1%), and the least commonly reported was Nausea (median 3.9%), but the reported percentages varied widely between
studies (Figure 2).
Full curation details are available in Supplemental File 2. Supplemental Figures S2-S26 provide an overview of the 287 phenotypic features arranged by category, and Supplemental Note 1 provides additional commentaries. Table 1 provides details on the vast
heterogeneity of symptoms, organised by the organ systems that
are likely to be involved. Few studies of long COVID to date have
conducted analyses elucidating the presence or extent of organ
damage. However, preliminary investigations of a number of organ systems have identiﬁed organ damage in long COVID patients.
These ﬁndings are important because they highlight the possibility
of asymptomatic long COVID patients sustaining organ damage due
to the SARS-CoV-2 virus that does not immediately present with
symptoms. Therefore, an improved understanding of organ damage
as an outcome of acute COVID-19 or as a long-term sequelae of the
SARS-CoV-2 virus may present new options for patients experiencing persistent symptoms or elucidate new information about how
the SARS-CoV-2 virus interacts with a range of organ systems.
In our study, we curated 287 HPO terms representing clinical
abnormalities observed in individuals following COVID-19. More
research will be needed to determine which of the terms, and potentially which additional terms, are speciﬁcally and causally related to SARS-CoV-2 infection. For instance, 10 phenotypic abnormalities in our study have also been reported to occur in PostIntensive Care Syndrome (PICS). While most of the manifestations
were reported to occur at similar frequencies, Dyspnea was more
commonly reported in patients following COVID-19 (Supplemental Figure S26). Additional comments are provided in Supplemental Note 2. It is conceivable that in some cases, the occurrence of
these ten manifestations in COVID-19 patients is related to care in
the ICU. However, all ten symptoms have also been reported in cohorts of individuals treated for COVID-19 as outpatients (Supplemental File 2).

2. Methods
We searched for publications on long COVID using CoronaCentral, which uses machine learning to process the literature on
SARS-CoV-2 [14]. We retrieved 303 articles predicted to be relevant to long COVID on April 29th, 2021. From these, 59 articles
described the clinical manifestations in clinical cohorts of individuals three weeks or more following acute COVID-19. We deﬁned
three weeks or more based on the initial appearance of symptoms
for outpatients or on three weeks or more after discharge for hospitalised patients. Descriptions of long COVID manifestations were
mapped to Human Phenotype Ontology (https://hpo.jax.org/app/)
terms. For this study, the HPO release 2021-06-08 was used. Four
curators, one with experience in long COVID and three with extensive experience in HPO curation, manually reviewed the articles
and identiﬁed HPO terms that corresponded to the description of
clinical abnormalities (symptoms, signs, laboratory abnormalities,
abnormal imaging ﬁndings) in the articles (Figure 1) and mapped
them in a spreadsheet. Each mapping was reviewed by all four
curators and discrepancies were resolved through discussion until consensus was reached. Some publications described multiple
time points (e.g., early and late), or varying severities of acute illness (e.g., critical/severe, moderate, mild), which were treated as
separate cohorts for the purposes of the current descriptive analysis (Supplemental Table S1). We tabulated the relationships between publications and the symptoms they reported, the mapped
HPO terms, and body systems (Supplemental Table S2).
The funders had no role in study design, data collection, data
analyses, interpretation, or writing of report.
3. Results
We reviewed 303 articles that were predicted to be relevant to
long COVID. We excluded articles that were reviews, related only
to acute-COVID timepoints, or did not provide suﬃcient details to
extract percentages for the symptoms (i.e., only provided averages
but not the number of patients affected in a cohort). Analysis of
the remaining 59 articles revealed a variety of criteria were used
to identify and evaluate patients with long COVID. The studies included 11 cohorts of patients who had been treated in the intensive care unit (ICU) during acute COVID-19, 36 cohorts of patients
who were hospitalised but not admitted to an ICU during the acute
phase, 16 cohorts of patients who were not hospitalised during
the acute phase, and 19 mixed cohorts. Some articles pulled data
from electronic health records (EHRs), while others strictly relied
on patient-reported symptoms from surveys. Studies also varied in
the method of collection and instruments used. Methods of collecting data came from phone or electronic surveys, in person review,
or pull from electronic medical records. For 26 cohorts, information was collected by in-person, telephone, email, or other online
3
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Figure 1. The HPO is arranged in a hierarchy from general to more speciﬁc. This graph shows a representative hierarchy of a portion of the HPO ‘abnormality of the
respiratory system’ branch. In this study, observations from 59 publications were mapped to the corresponding HPO terms (nodes). A selection of the original terminology
used in the manuscripts (in italics) is shown adjacent to the HPO term to which it was mapped. A detailed list of all mapped terms is provided in Supplemental File 2.

4. Discussion

stood, and the molecular mechanisms underlying these post-acute
presentations have yet to be elucidated.
Post-infectious sequelae have also been documented following
infection by other coronaviruses. A subset of patients with severe acute respiratory syndrome (SARS), caused by the coronavirus
SARS-CoV, and Middle-Eastern Respiratory Syndrome (MERS),
caused by the coronavirus MERS-CoV, were observed to experience
persistent or new-onset symptoms, including fatigue [19], following recovery from the acute infection [19–21]. For SARS, follow-up
has been conducted up to 15 years post-infection. In addition to fatigue, studies reported effects on lung health and capacity [22–25],
psychological health [19], bone health [25], and lipid metabolism

The fact that some COVID-19 patients experience symptoms
following recovery from acute infection is not unexpected. Other
infectious diseases, including Epstein-Barr Virus, Giardia lamblia,
Coxiella burnetii, Borrelia burgdorferi (Lyme disease) and Ross
River virus are also associated with an increased risk for postinfectious sequelae. These sequelae include symptoms such as
disabling fatigue, musculoskeletal pain, neurocognitive diﬃculties,
and mood disturbance [15–17]. Chronic fatigue syndrome (CFS) is
frequently preceded by a viral infection [18]. However, although
these sequelae are well documented, they are still not well under-
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Figure 2. Reported frequencies for the 25 phenotypic features identiﬁed in 12 or more cohorts. Box plots are shown for each item, displaying the minimum (1.5 times the
interquartile range below the lower quartile), ﬁrst quartile, median, third quartile, and maximum (1.5 times the interquartile range above the upper quartile). Outliers are
shown as dots. DLCO: diffusing capacity of the lungs for carbon monoxide, FEV1: forced expiratory volume in one second; TLC: total lung capacity.

[26], with the latter two attributed to treatments involving large
doses of steroids [25,26]. Most of the improvement among SARS
patients occurred within the ﬁrst one to two years following infection [25,27,28]. Some patients continued to experience decreased
quality of life for more than a decade following the acute illness
[26]. Though follow-up studies in MERS patients are sparse, effects
on pulmonary function were observed at one year post-infection,
with patients who experienced more severe disease at greater risk
for long-term effects [29].
Long-term consequences of COVID-19 comprise an unprecedented range of clinical abnormalities that we are barely beginning
to understand. These symptoms appear to arise from pathophysiologic changes that span many organ systems and tissues, potentially explained by SARS-CoV-2’s interaction with the endothelium
[30]. A wide range of outcomes following acute COVID-19 have
emerged as more information about patient recovery has been
collected and pathophysiologic mechanisms are revealed. Some
patients experience residual symptoms and others develop new

symptoms long after the initial infection. Given the timeline of
SARS-CoV-2’s emergence, studies to date have tracked patients’
clinical course up to six months post-infection [31–33], but anecdotal reports are available describing patients with ongoing symptoms as long as one year post-infection [34]. Symptoms experienced after the acute illness represent a signiﬁcant challenge for
patients, physicians, and society as a whole. The causes, patient
proﬁle, and even symptom patterns associated with long COVID
remain diﬃcult to isolate, and the natural history of this condition remains uncharacterised. Goals of research on long COVID
include understanding the natural history of the disease including the prognosis of the many individual manifestations of disease, whether there are well delineated subtypes, whether speciﬁc
characteristics of the acute phase of COVID-19 predispose to long
COVID, and what treatments may best accelerate recovery. Here,
we have reported 287 HPO terms representing clinical anomalies
reported as long COVID in persons following acute COVID-19. For
some of the terms, such as those reported only once to date, fur-
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12.8% (n=44)
22.2% (n=24)
20.4% (n=4)
18.6% (n=13)
18.8% (n=9)
21.1% (n=25)
26.5% (n=2)
3.8% (n=29)
45.1% (n=48)
26.0% (n=6)
1.0% (n=7)
9.7% (n=7)
13.8% (n=36)
31.5% (n=18)
16.8% (n=8)
0.8% (n=29)
35.1% (n=56)
31.9% (n=12)

Median Percent (number of cohorts)

One of the challenges in characterizing long COVID is the fact
that patients report symptoms that may not be captured by clinical
evaluation or in standard surveys. To truly characterise long COVID
and therefore stratify patients into subtypes for care decisions,
it is necessary to engage patients directly in the description of
their long COVID features. However, medical terminology is often
perplexing to patients, making it diﬃcult for patient-researchers
to use resources like the HPO. Patients themselves are an eager
and untapped source of accurate information about symptoms and
phenotypes, some of which may go unnoticed by the clinician [6].
Patients and clinicians use different terms to describe the same
symptoms or conditions. In many cases, the clinical term is an
exact match to the layperson synonym; however, other times the
layperson terminology is less precise. HPO allows layperson synonyms to be mapped to an ontology, with more speciﬁc terms
being deﬁned as subtypes of more general terms. Mapping lay
terminology to HPO for long COVID symptoms will help patients
assist clinicians and researchers in creating robust computational
phenotype proﬁles, which may improve the diagnosis and treatment of long COVID. Here, we systematically abstracted 287 long
COVID manifestations including signs, symptoms, and laboratory as
well as imaging abnormalities, added layperson synonyms where
missing, and mapped layperson to HPO terminology. We wrote
plain-language deﬁnitions for these terms to supplement the existing deﬁnitions that are aimed at healthcare professionals and researchers. [35](35). A full list is available in the supplemental material in human and computer readable form. This common set of
deﬁnitions can promote integration of research by translating between patient and clinician descriptions of symptoms. We anticipate that these terms, synonyms and deﬁnitions will be a critical
resource for use in survey instruments and patient apps for standardizing patient-reporting in the future study of long COVID.
In addition to using different terms, inaccurate terms have also
been used to describe some symptoms of long COVID. For example, “loss of smell” is a commonly reported problem facing patients
during both acute infection and long COVID. However, this term is
often used to describe both true “loss of smell”, anosmia, and also
mistakenly used for “distorted smell,” or parosmia. Parosmia is a
qualitative disorder of smell that is deﬁned by distorted olfactory
perception in the presence of an existing stimulus [36]. Parosmia in
COVID-19 has been reported as an unpleasant perception of odorants (troposmia) that follows anosmia and may persist for several
months [37]. Post-viral parosmia has been suggested to develop
in the olfactory neuron regeneration phase due to a preponderance of immature neurons during re-innervation [38]. This concept
has been proposed for COVID-19 related parosmia as well due to
a similar pattern of succession [39]. Parosmia was not speciﬁcally
noted in the studies reviewed for this work, but has been shown
to have a high prevalence in acute and post-acute COVID-19 associated parosmia [40].
The HPO layperson synonym mapping from this study will
facilitate the construction of common data elements related to
long COVID research. A strategic plan of the National Library of
Medicine (NLM) 2017-2027 and a recent NIH strategic plan for
data science identify common data elements as a means by which
to improve data interoperability across studies [41]. Developing a
standardised vocabulary with HPO mapped to layperson terms to
characterise long COVID symptoms and ﬁndings will provide valuable guidance in building common data elements for textual and

7
17
16
8
10
9
9
10
23
23
30
13
9
16
15
18
14
7

Anosmia (HP:0000458)
Anxiety (HP:0000739)
Hypertension (HP:0000822)
Cognitive impairment (HP:0100543)
Alopecia (HP:0001596)
Depression (HP:0000716)
Hepatic steatosis (HP:0001397)
Diarrhea (HP:0002014)
Fatigue (HP:0012378)
Elevated circulating D-dimer concentration (HP:0033106)
Dysphagia (HP:0002015)
Blurred vision (HP:0000622)
Myalgia (HP:0003326)
Decreased DLCO (HP:0045051)
Parenchymal consolidation (HP:0032177)
Fever (HP:0001945)
Dyspnea (HP:0002094)
Insomnia (HP:0100785)

Total reported features

abnormalities of smell and taste
behavioral abnormalities
cardiovascular ﬁndings
cognitive dysfunction
dermatological ﬁndings
emotion/mood abnormalities
gastrointestinal ﬁndings
gastrointestinal symptoms
general symptoms
laboratory abnormalities
neuropsychiatric ﬁndings
ocular abnormalities
pain
pulmonary ﬁndings
pulmonary imaging ﬁndings
reproductive, genitourinary, endocrine, or metabolism ﬁndings
respiratory symptoms
sleep impairment

Most commonly reported feature

4.1. Linking layperson and health-professional research

Category

Table 1
Overview of abnormal phenotypic ﬁndings by category. The most commonly reported ﬁndings are shown for each category. The total number of features reported in each organ system is shown in
the second column. Categories with at least 7 features are shown. The median percent column shows the median for the percentage of patients with the feature indicated in the previous column,
together with the number of cohorts reporting the feature. Supplemental File S2 provides details.

ther research will be required to determine if the abnormalities are
speciﬁcally related to COVID-19 and their frequency. We have presented plain-language ‘translations’ of all terms that can be used
to create patient questionnaires.
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imaging annotation schema as well as creating patient-centered
measurement instruments and clinical surveys.
As long COVID related data increasingly accumulates in EHRs,
it is promising to generate practice-based evidence through the
secondary use of EHR. However, it is challenging to conduct such
research without using natural language processing (NLP), since
much information is only stored in unstructured clinical narratives; additionally, because many providers are unfamiliar with the
vast array of long COVID symptoms, many are not recorded in
these narratives. The layperson deﬁnitions and associated synonym
mapping would greatly accelerate the development and evaluation
of NLP algorithms for extracting long COVID signs and symptoms
from EHRs. Baseline NLP algorithms based on HPO can be implemented. Speciﬁcally, a fast trie based string matching approach can
spot long COVID terms on the ﬂy in massive clinical corpora for
near real-time interactive analyses of long COVID phenomena from
EHR data. A many-to-one mapping from synonyms to HPO terms
identiﬁed in this effort will then facilitate more rapid long COVID
analytics. Additionally, this effort would enable the rapid development of an annotation guideline for generating benchmarking
data, a critical component in developing and evaluating NLP algorithms. If this annotation includes notes from several sites, even
spelling mistakes (that nevertheless refer to long COVID terms) can
be spotted by ﬁrst building a named entity recognition (NER) tool
and then mapping mentions to long COVID HPO terms through approximate matching via neural word embeddings constructed from
character-based neural language models. Another important affordance of this effort is to be able to mine social media posts for
long COVID disclosures from patients and healthcare consumers to
complement EHR-derived surveillance [42](preprint).
As the National COVID Cohort Collaborative (N3C) established
a collaboration among multiple organizations through pandemic
data sharing, i.e., Common Data Model (CDM), the long COVID concept standardization enabled by this study will play an indispensable role in achieving the semantic interoperability for the secondary use of EHR among multiple sites.

the deﬁnitions used in the literature. For example, a recently proposed public health framework classiﬁes SARS-CoV-2-related disease into three categories [44]. The ﬁrst is acute COVID-19, or
the disease most commonly associated with acute SARS-CoV-2 infection. The second category includes Multisystem Inﬂammatory
Syndrome in Children (MIS-C) and in adults (MIS-A), a less common presentation of SARS-CoV-2 infection characterised by hyperinﬂammation that can appear 4-6 weeks after viral infection [45].
The third category describes late sequelae [44]. In terms of deﬁning study cohorts, adherence with this deﬁnition would require a
clinical diagnosis, rather than a SARS-CoV-2 test alone, to distinguish MIS-C/A and COVID-19. While it appears too early to propose
a set of computable deﬁnitions for the various types of disease associated with SARS-CoV-2 (because we are still learning about the
natural history), it would be advantageous for studies to apply a
currently accepted deﬁnition of long COVID and to describe details
in the methods. Studies should denote comorbidities using a standard ontology of diseases such as Mondo [46].
Additionally, in many cases it is diﬃcult to know if a clinical
abnormality was present prior to acute COVID-19 and was merely
diagnosed by investigations and additional clinical tests that were
performed following the diagnosis of COVID-19. For instance, Hepatic steatosis was reported to be more common in individuals following acute COVID-19 infection in a single study [47]. However,
this is a common ﬁnding in the general population and additional
research will be required to characterise its precise relation to long
COVID.
The studies analyzed in this work varied widely in the terminology used to describe patient-reported symptoms as well as clinical signs, laboratory abnormalities, and imaging ﬁndings. For example, the studies analyzed included a mixture of reports of ageusia [48,49], anosmia [48,49], anosmia/ageusia [50], loss of smell
[51,52], loss of taste [51], loss of smell and taste [53], loss of
smell or taste [54], and loss of smell and/or taste [55]. While in
many cases there are parallels among studies (e.g., studies reporting anosmia and loss of smell are likely to be asking the same
or similar questions of patients), the lack of a strict deﬁnition
prevents straight-forward symptom matching across multiple published analyses. Different studies measure clinical manifestations in
different ways. For instance, the presence of fatigue can be measured by a yes/no question in an online questionnaire or can be
inferred from the results of a multidimensional study instrument
such as the Short Form-36 Vitality scale [56]. In such cases, standard use of a full terminology such as HPO would be useful to create expressive and consistent meaning across studies. Future studies should make data available using either the HPO terms provided here or other terms from the full collection of over 16,0 0 0
HPO terms.
From a clinical standpoint our work demonstrates that managing long COVID patients will require a multidisciplinary effort.
Given that respiratory system ﬁndings and fatigue were the most
common, a pulmonologist with a pulmonary rehabilitation program will be one of the cornerstones of any long COVID management program. At the same time considering the high frequency
of psychiatric and neurological symptoms, psychiatrists and neurologists with specialization in neurocognitive testing and treatment will be necessary. Furthermore given the extreme variation
in symptoms and presentation, a primary care internist will have
to be responsible for coordinating the care of long COVID patients
with appropriate referrals when required. Taking into account the
high frequency of long COVID in survivors primary care physicians
will have to be made aware of the myriad presentations of long
COVID with active screening for long COVID. Primary care physicians will need to refer long COVID patients to dedicated long
COVID management programs.

4.2. Improving future research on the natural history of long COVID
All published studies analyzed in this work present their results in aggregate rather than providing row level data for each
participant. This prevents most data reuse to analyze correlations
between comorbidities and risk for long COVID or for speciﬁc manifestations of long COVID, and this makes it impossible to investigate potential correlations between long COVID manifestations.
Therefore, future studies should present non-identiﬁable information about individual patients. This will allow correlations between
variables. Also, studies need to use controlled vocabulary to classify
patients and need to agree on a minimal set of information. Presenting (non-identiﬁable) data in the form of a table with one row
per patient would be a great improvement over the current status.
More sophisticated strategies for recording individual clinical histories are available, such as the Global Alliance for Genomics and
Health phenopacket schema [43].
The majority of studies included in this analysis did not apply
inclusion criteria to correspond to any speciﬁc deﬁnition of long
COVID, but instead studied groups of patients who had previously
undergone infection by SARS-CoV-2 with a range of manifestations
in the acute phase. Long COVID can be broadly deﬁned as delayed
recovery from an episode of COVID-19 and is characterised by lasting effects of the infection, e.g., persistence of symptoms or onset
of new chronic diseases, for longer than would be expected [8].
Although no ﬁrm criteria have been established to deﬁne the postacute period or sub-categories within long COVID, several sets of
guidelines have been proposed for the classiﬁcation of COVID-19related disease phenotypes, and these criteria were compared to
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Working toward computable long COVID phenotypes in this
way will improve our ability to understand the natural history of
long COVID. Such phenotypes will also allow observational analyses of factors that may reduce long COVID symptoms. The standardised phenotypic features and synonyms bundled in the HPO
terms presented here are a foundation for natural language processing of EHR data, clinical decision support tools, and analytic
approaches such as machine learning.
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